The utility of a telemedicine platform to monitor adherence and adverse effects of tyrosine kinase inhibitors

Anureet C. CopelandDepartment of Hematology/Oncology, University of North Carolina, Chapel Hill, NC, USA; Correspondence[email protected]

Matthew C. FosterDepartment of Hematology/Oncology, University of North Carolina, Chapel Hill, NC, USA;

Benyam MulunehDepartment of Pharmacy, University of North Carolina, Chapel Hill, NC, USA;

James G. XenakisDepartment of Biostatistics, University of North Carolina, Chapel Hill, NC, USA;

Anastasia IvanovaDepartment of Biostatistics, University of North Carolina, Chapel Hill, NC, USA;

Olga FrankfurtDepartment of Hematology/Oncology, Northwestern University, Chicago, IL, USA;

Monique ClaytonDepartment of Hematology/Oncology, University of North Carolina, Chapel Hill, NC, USA;

Anderson BlackUNC Rex Healthcare, Raleigh, NC, USA;

Barbara RapchakLeap of Faith Technologies, Crystal Lake, IL, USA

Robert S. WehbieUNC Rex Healthcare, Raleigh, NC, USA;

show all

References

Jabbour E, Saglio G, Radich J, et al. Adherence to BCR-ABL inhibitors: issues for CML therapy. Clin Lymphoma Myeloma Leuk. 2012;12:223–229.
PubMed Web of Science ®Google Scholar
Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. Jco. 2009;27:6041–6051.
PubMed Web of Science ®Google Scholar
Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113:5401–5411.
PubMed Web of Science ®Google Scholar
Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. Jco. 2010;28:2381–2388.
PubMed Web of Science ®Google Scholar
Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59:56–66.
PubMed Web of Science ®Google Scholar
Pulsifer K. Pilot Program Revolutionizes Outpatient Care for At-Risk Patients. Philadelphia: NBC 10 Philadelphia News; 2015.
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

The utility of a telemedicine platform to monitor adherence and adverse effects of tyrosine kinase inhibitors

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The utility of a telemedicine platform to monitor adherence and adverse effects of tyrosine kinase inhibitors

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date